The Belt, 2131. A group of miners has filed suit against Apex Orbital Extraction alleging systematic discrimination against non-augmented employees — the first case of its kind to reach a UN labor tribunal since cybernetic augmentation became common in hazardous extraction work. The filing lands amid a separate, harder-to-litigate development: the emergence of a decentralized collective calling itself the Biohackers, distributing self-administered gene therapies that claim to match cybernetic performance without a single mechanical component — and a regulatory framework that, as written, may not have an answer for either problem.
The Complaint
The plaintiffs — twelve miners across three Apex Orbital extraction sites — allege that promotion into higher-hazard, higher-pay extraction roles has become functionally contingent on cybernetic augmentation for strength, endurance, and radiation tolerance, regardless of formal job postings that describe the requirement only as “enhanced physical capacity, method unspecified.” Several plaintiffs report being reassigned to lower-tier surface logistics roles after declining augmentation on religious, medical, or personal grounds; one reports outright termination.
Apex Orbital’s response, filed alongside a motion to dismiss, does not deny that augmented workers are disproportionately represented in the roles in question — only that this reflects performance outcomes rather than a stated policy. “We hire and promote based on documented capability against the demands of the role,” an Apex Orbital spokesperson told UN Weekly. “If augmentation happens to correlate with meeting that bar, that is a fact about the work, not a preference of ours.”
Where the Biohackers Complicate Everything
That defense was already shakier than it looked before the Biohackers entered the picture. The collective — structure and leadership deliberately opaque, distribution informal and cash-or-barter — has spent the past year circulating a gene therapy regimen: a course of engineered stimulant and muscle-density modifications, paired with a focus-sharpening neurochemical adjustment, self-administered rather than clinically delivered. Users report performance gains — strength, endurance, sustained attention — that Belt engineering circles describe as comparable to entry-level cybernetic augmentation, achieved without a single embedded mechanical component.
That distinction is not incidental. It exposes something closer to a legal void than a loophole. The UN Charter on the Governance of Embodied Cognitive Systems (2052) was never written as an augmentation-licensing framework — its actual subject, per Article 1, is embodied platforms paired with cognitive-intelligence systems: physical robotic systems capable of independent locomotion and manipulation, equipped with reasoning of some kind. Most cybernetic strength and endurance augmentation used in Belt extraction work has no onboard reasoning system at all — it’s mechanical and electrical, not cognitive — and so was never within the Charter’s scope to begin with. The one place the Charter does reach into human augmentation is a narrow precedent: prosthetics built around a neuromotor bridge, of the kind Anthros licensed under Article 4.2 in 2093, count as an embodied platform carrying specialized-function reasoning, and require certification for exactly that reason. A simple strength-augmenting limb without any reasoning component does not.
Gene therapy of the kind the Biohackers distribute was never going to be covered either, for an even more basic reason: it introduces no embodied platform of any kind. The upshot is not that gene therapy dodges a rule cybernetics has to follow — it’s that neither one is meaningfully addressed by the only binding international framework that touches augmentation at all, except at that one narrow edge. Apex Orbital’s hiring practice, and the plaintiffs’ claim against it, are both operating in a space no legislature actually designed.
That gap now sits directly inside the discrimination case. At least three of the twelve plaintiffs have privately begun using Biohacker treatments since the suit was filed — meaning, under Apex Orbital’s own stated policy of hiring by “documented capability… method unspecified,” those plaintiffs may now meet the very performance bar they are suing over having been denied, without qualifying as “augmented” under any definition currently written into law or company policy. Apex Orbital declined to say whether gene-therapy-enhanced performance would satisfy its promotion criteria going forward.
Voices
A plaintiff, speaking on condition of anonymity: “I didn’t want a machine put in my arm to keep my job. I don’t know what I want less — that, or whatever this new thing is. I just wanted the job I already had.”
A Biohacker collective representative, reached through an encrypted relay and identified only by the handle Splice: “We’re not selling augmentation. We’re selling the same outcome without asking anyone’s permission to modify their own body, and without a company or a UN office owning the hardware inside you. If that undercuts the labor argument for cybernetics, good. That was never the point, but I won’t pretend I’m sorry about it.”
A labor law scholar at Pobeda University, asked to characterize the regulatory gap: “The 2052 Charter was written to answer ‘is this a robot,’ not ‘is this still a body.’ Nobody drafting embodiment law twenty years ago was thinking about gene therapy that doesn’t touch cognition at all. This case may be the first time a court has to decide whether that gap was an oversight or a genuine boundary.”
Status
The tribunal has not yet ruled on Apex Orbital’s motion to dismiss. No date has been set for a substantive hearing.